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Background: The optimal way for antimicrobial stewardship programs (ASPs) to interact with existing infectious
disease physician (IDP) services within the same institution is unknown. In our institution, IDPs and our prospective
audit and feedback ASP operate independently, with occasionally differing recommendations offered for the same
inpatient. We performed a retrospective audit on inpatients that had been reviewed by both IDPs and ASP within
a 7-day period, focusing on cases where different therapy-modifying recommendations had been offered. We
analyzed the outcomes in inpatients where the ASP recommendations were accepted and compared these with
the inpatients where the IDP recommendations were accepted instead. Outcomes assessed were 30-day mortality
post-ASP review, unplanned re-admission within 30 days post-discharge from hospital, and clinical deterioration at
7 days post-ASP review.
Findings: There were 143 (18.9%) patients where differing recommendations had been offered, with primary
physicians accepting 69.9% of ASP recommendations. No significant differences in terms of demographics, clinical
characteristics, 30-day mortality, and re-admission rates were observed, although clinical deterioration rates were
lower in patients where the ASP recommendation was accepted (8.0% vs. 27.9%; p=0.002). On multivariate analysis,
hematology-oncology inpatients were associated with unplanned readmission. Increasing age and hematology-
oncology inpatients were associated with clinical deterioration 7 days post-recommendation, whereas acceptance
of ASP recommendations was protective. No characteristic was independently associated with 30-day mortality.
Conclusion: In conclusion, independent reviews by both IDPs and ASPs can be compatible within large tertiary
hospitals, providing primary physicians even in situations of conflicting recommendations viable alternative
antimicrobial prescribing advice.
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Introduction
Infectious diseases (ID)-trained physicians are consid-
ered integral to antimicrobial stewardship programs
(ASPs), conferring program legitimacy with regards to
other hospital physicians and ensuring that ASP activ-
ities do not put patients at greater risk of adverse* Correspondence: liyang_hsu@yahoo.com
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reproduction in any medium, provided the oroutcomes [1]. However, there can be considerable vari-
ability in the antibiotic prescribing practices of ID physi-
cians [2,3], particularly if they had received training at
different institutions.
In institutions with both an ID service and an ASP, it
is inevitable that broad-spectrum antibiotics prescribed
to patients by their primary physicians based on advice
by ID physicians will come under the ambit of the ASP.
It is also inevitable that there will be differences between
ID physicians’ and the ASP’s clinical interpretations with
respect to antibiotic prescribing in a subset of these
cases. How an ASP should function in such situations. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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although three main courses of action are apparent:
 Disregard all patients where an ID physician’s
clinical input has been sought.
 Review such patients, but contact the ID physician
should the ASP’s view not coincide with the ID
physician’s recommendations, and come to an
agreed recommendation.
 Review such patients and submit an ASP
recommendation independently.
Each approach has its advantages and disadvantages in
terms of oversight, clinical authority (of both ID physi-
cians and the ASP), impact of the ASP on antibiotic pre-
scribing rates, and collegiality. In our institution, where
a prospective audit and feedback ASP has been estab-
lished since 2009 [4], we have consistently taken the last
approach. We present herein our experience where ASP
and ID physicians provide independent assessments and
recommendations, analyzing the outcomes of a large
subset of cases where the recommendations have
differed.
Setting and methods
We performed a retrospective analysis on all patients
reviewed concurrently by ID physicians and the ASP be-
tween 1st August 2011 and 30th November 2012 at our
institute – a 994-bed tertiary university hospital. ID phy-
sicians provide a standard referral service whereas the
prospective audit and feedback system of our ASP is also
standard and has been described elsewhere [4,5]. Clinical
and demographic data were extracted from our ASP
database as well as the hospital electronic records. The
Charlson comorbidity index was used as an aggregate
measure for patients’ comorbidity prognostication [6].
The unit of measurement was a patient that had been
reviewed within one week by both an ID physician and
the ASP. Patients where differing therapy-modifying rec-
ommendations were made by the ID physician and the
ASP were selected for more in-depth analysis of out-
comes. Outcome measures include 30-day mortality
post-ASP review, unplanned re-admission within 30 days
post-discharge from hospital, and clinical deterioration
at 7 days post-ASP review – a composite measure com-
prising persistence of fever (if febrile), failure of micro-
biological clearance, and lack of general physiological
improvement defined by the primary physicians’ records.
Intercooled Stata 12.1 (StataCorp, College Station,
USA) was used for all statistical calculations, with the
level of significance set at 5%. For determination of co-
variates associated with the various outcomes, we per-
formed logistic regression, with a multivariate model
based on covariates identified in the univariate analysis(p-value <0.200) using the likelihood ratio test, with
probability of removal set at 0.05.
The NUH Medical Board approved this work.
Informed consent was not obtained from individual
patients as both the operations of ID physicians and
the ASP constituted routine clinical practice, and only
anonymized data were analyzed.
The National University Health System funded this
work internally and had no role in study design, analysis
or write-up of the results.
Results
There were 756 patients within the audit period that had
concurrently been reviewed by both ID physicians and
the ASP, of which 143 (18.9%) had differing therapy-
modifying recommendations. The clinical, demographic
and outcome data for these patients are shown in
Table 1, classified by whether ASP recommendations
(100 cases; 69.9%) or ID physicians’ recommendations
were accepted. In the majority of these cases, ID physi-
cians generally recommended continuation of broad-
spectrum antibiotics rather than de-escalation, longer
duration of antibiotics, or combination antibiotics (par-
ticularly for Pseudomonas aeruginosa infections).
The majority of patients were from the surgical disci-
plines (54.5%) or the hematology-oncology department
(33.6%). There was no significant difference in terms of
demographic or clinical characteristics for patients
where the ASP recommendations had been accepted or
rejected in favor of ID physicians’ recommendations, al-
though physicians of patients with bone and joint infec-
tions had higher rates of acceptance of ID physicians’
recommendations, with the converse being true for phy-
sicians of patients with undifferentiated fevers or where
no infection was present.
There was no difference in 30-day mortality or 30-day
re-admission rates between the two groups, although
clinical deterioration rates were lower in patients where
the ASP recommendations had been accepted. Six of 10
deaths occurred in patients with advanced cancers who
were on palliative care.
The results of univariate analysis of demographic and
clinical characteristics with outcomes are shown in
Table 2. Multivariate analysis was not performed for 30-
day mortality as none of the demographic or clinical
characteristics had a p-value <0.200 on univariate ana-
lysis. The only characteristic associated with unplanned
readmission 30 days post-recommendation was being
from the hematology-oncology department (OR=4.133;
95% CI: 1.301 – 13.122; p=0.016). Increasing age
(OR=1.043; 95% CI: 1.003 – 1.085; p=0.037) and being
from the hematology-oncology department (OR=6.116;
95% CI: 1.352 – 27.665; p=0.019) was associated with clin-
ical deterioration 7 days post-recommendation, whereas
Table 1 Demographic, clinical and outcome data of 143 patients with differing therapy-modifying recommendations
by ASP and ID physicians
ASP recommendation accepted ID physician recommendation
accepted
p-value
(n = 100) (n = 43)
Median age, years (interquartile range) 64 (53–72) 58 (50 – 72) 0.393
Intensive care unit admission within 30 days prior to review (%) 23 (23.0) 10 (23.3) 0.973
Median Charlson Comorbidity Index (interquartile range) 5 (3 – 8) 5 (2 – 8) 0.255
Clinical discipline (%) 0.754
• Hematology-oncology 36 (36.0) 12 (27.9)
• Surgery 29 (29.0) 12 (27.9)
• Orthopedics 24 (24.0) 13 (30.2)
• Medicine 10 (10.0) 6 (14.0)
• Others 1 (1.0) 0 (0)
Type of infection (%): 0.247
• Intra-abdominal infection 23 (23.0) 9 (20.9)
• Bloodstream 12 (12.0) 6 (14.0)
• Bone and joint infection 14 (14.0) 12 (27.9)
• Skin and soft tissue infection 15 (15.0) 6 (14.0)
• Respiratory tract infection 6 (6.0) 2 (4.7)
• Urinary tract infection 10 (10.0) 6 (14.0)
• Othersa 20 (20.0) 2 (4.7)
Type of ASP recommendations:b 0.172
• Discontinue antibiotics 26 5
• De-escalate antibiotics 30 16
• Escalate antibiotics 8 5
• Intravenous to oral antibiotic switch 6 2
• Dose optimization 16 5
• Duration of antibiotics 0 2
• Discontinue duplicate antibiotic coverage 9 7
• Other recommendationsc 10 3
Outcomes (%):
• 30-day mortality 7 (7.0) 3 (7.0) 1.000
• 30-day re-admissiond 21 (22.6) 6 (15.0) 0.358
• Clinical deterioration 8 (8.0)e 12 (27.9)f 0.003
○ Persistent fever 2 (25.0) 4 (33.3)
○ No microbiological clearance 2 (25.0) 3 (25.0)
○ Lack of physiological improvement 6 (75.0) 10 (83.3)
a“Others” include undifferentiated fevers, viral infections, and no infection.
bThere were 150 ASP recommendations for 143 patients.
c“Other recommendations” include switching to less expensive carbapenems (9 cases), streamlining antibiotics (2 cases) and addition of antifungal agents
(2 cases).
dPatients who had died are excluded.
eOne patient had persistent fever and bacteremia; one patient had persistent fever with hypotensive episodes; one patient had persistent candidemia with
respiratory distress.
fTwo patients had persistent fever and persistent positive wound cultures; one patient had persistent fever and bacteremia with cardiac failure; one patient had
persistent fever with hypotension.
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Table 2 Univariate analysis of the impact of cohort characteristics with outcomes














Higher age 1.015 0.968 – 1.064 0.545 1.021 0.989 – 1.055 0.198 1.027 0.990 – 1.064 0.155
Prior ICUa admission 0.351 0.043 – 2.875 0.329 0.975 0.355 – 2.725 0.975 0.547 0.150 – 1.996 0.361
Higher Charlson co-morbidity index 1.064 0.871 – 1.301 0.542 1.033 0.897 – 1.190 0.653 1.028 0.884 – 1.194 0.724
Clinical discipline (relative to surgery)
• Hematology-oncology N.A.* N.A.* N.A.* 3.855 1.241 – 11.980 0.020 3.462 0.875 – 13.693 0.077
• Orthopedics 0.452 0.085 – 2.390 0.265 1.720 0.453 – 6.530 0.426 3.333 0.770 – 14.436 0.107
• Medicine 1.273 0.225 – 7.197 0.792 1.911 0.319 – 11.450 0.478 2.727 0.405 – 18.358 0.302
• Others N.A.* N.A.* N.A.* N.A.* N.A.* N.A.* N.A.* N.A.* N.A.*
Type of infection
(relative to intra-abdominal infections)
• Bloodstream 0.882 0.074 – 10.464 0.921 0.438 0.080 – 2.400 0.342 1.080 0.226 – 5.162 0.923
• Bone and joint infection 1.957 0.302 – 12.692 0.482 0.493 0.112 – 2.164 0.349 1.286 0.329 – 5.032 0.718
• Skin and soft tissue infection 1.579 0.205 – 12.173 0.661 0.616 0.138 – 2.749 0.526 N.A.* N.A.* N.A.*
• Respiratory tract infection N.A.* N.A.* N.A.* 1.095 0.179 – 6.694 0.922 0.771 0.077 – 7.712 0.825
• Urinary tract infection 1.000 0.084 – 11.931 1.000 0.548 0.098 – 3.057 0.492 1.246 0.257 – 6.031 0.784
• Others 0.750 0.064 – 8.834 0.819 1.095 0.293 – 4.097 0.526 0.900 0.191 – 4.243 0.894
ASP recommendation accepted 1.004 0.247 – 4.079 0.996 1.412 0.517 – 3.859 0.501 0.225 0.084 – 0.600 0.003
aICU = intensive care unit.
*N.A. = predicted failure of regression perfectly (none or all patients in this category).
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0.050 – 0.457; p=0.001) was protective.
Discussion
The most effective way to implement antimicrobial stew-
ardship is not known at this point in time [7], but is
probably strongly influenced by local practices, history
and culture. Both ID physicians (not involved in anti-
microbial stewardship) and ASPs should ideally support
the concept of antimicrobial stewardship and appropri-
ate prescription of antimicrobial agents [1,7]. However,
there may be differences in the perceived importance of
various aspects of clinical care, leading at times to radic-
ally different antimicrobial prescribing recommenda-
tions. As an example, institutional antimicrobial
resistance rates and the differential costs of antibiotics
may matter far less to an ID physician than an ASP,
resulting in a more conservative approach to de-
escalating or stopping antibiotics in patients that have
more complications or a slower clinical response, re-
gardless of culture results.
In an institution with both ID physicians and an ASP,
there may also be professional friction if one is seen to
encroach on the clinical domain of the other. Patients’
primary physicians may also be confused if conflicting
recommendations were received from the ID physicians
and the ASP. In the majority of local institutions, theASPs do not audit patients who are under the active re-
view of an ID physician (data not shown). Nonetheless,
there may be benefits for patients – particularly in large
clinical institutions with high patient workload – if ASPs
and ID physicians provide independent reviews and
cross-checks, providing an answer to the perennial ques-
tion of “quis custodiet ipsos custodes” (who shall watch
the watchmen) in the context of antimicrobial prescrib-
ing and stewardship. Our results suggest that such an
approach can be complementary. Concordant recom-
mendations were made for the vast majority of patients
reviewed by both ASP and ID physicians. Where recom-
mendations have differed, patients did not have worse
outcomes when the ASP’s recommendations were pre-
ferred. Although patients where the ASP recommenda-
tions were accepted appeared to have better clinical
response at Day 7 post-recommendation, it is plausible
that this is confounded by primary physicians preferring
ID physicians’ recommendations over ASP recommen-
dations in the setting where patients had been more ill
or were clinically deteriorating. Unfortunately there were
insufficient data and patients to clarify this. Anecdotally,
primary physician confusion was minimal, with most
teams recognizing the different roles and review pro-
cesses of the ID physicians and the ASP.
A compromise approach would be to initiate discussions
between ID physicians and the ASP each time there is a
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dations. This will reduce although probably not eliminate
conflicting recommendations to the patients’ primary phy-
sicians, and may be ideal in most institutional settings
where the clinical workload is not overwhelming.
Our other results are unsurprising in finding that
higher age and having a hematological or oncological
(the patients mostly had hematological malignancies)
condition were associated with subsequent clinical de-
terioration, and most unplanned admissions for patients
from this department were for the development of fe-
brile neutropenia post-chemotherapy. Because data for
calculating acute physiological scores were not collected
as part of the study, and the number of deaths was rela-
tively small, there were no significant co-variates associ-
ated with 30-day mortality found.
Our audit is primarily limited by the relatively small
patient numbers and the methodology. The definition of
clinical deterioration was also very broad and data col-
lection for this variable was performed as a routine func-
tion of the ASP (and therefore not blinded with respect
to whether ASP recommendations were accepted).
Nonetheless, the results appear robust and it is difficult
if not impossible to run a prospective study within a sin-
gle institution – perhaps cluster randomization will be
required to determine if an approach of independent re-
views and recommendations by both ID physicians and
ASPs will positively benefit clinical care. We have also
not rigorously audited the results in terms of the cost-
savings of ASP recommendations vis-à-vis ID physicians’
recommendations. One final major limitation of this audit
is that the findings may not be applicable outside of our
institution or country, as cultural differences may signifi-
cantly affect the success or failure of such practices.
In conclusion, we have demonstrated that independent
reviews by both ID physicians and ASPs can be compatible
within a large tertiary university hospital, providing pri-
mary physicians even in situations of conflicting recom-
mendations viable alternative antimicrobial prescribing
recommendations. This approach will also not result in so-
cial or professional conflict between ID physicians and
ASPs provided that communication is good. Initiating early
discussions between ID physicians and ASPs in situations
where antimicrobial prescribing advice differs may signifi-
cantly reduce the number of conflicting recommendations.
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